06.04.2016 21:50:00
|
Wyeth -- Moody's affirms Pfizer's A1/Prime-1 ratings; stable outlook
New York, April 06, 2016 -- Moody's Investors Service affirmed the ratings of Pfizer Inc. and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating. The outlook is stable. This rating action follows the announcement that Pfizer and Allergan Plc have mutually terminated their planned merger following recent changes to US tax rules related to inversion transactions.